If a pharmaceutical company wished to design a drug to maintain low blood sugar levels, one approach might be to design a compound

A) that mimics epinephrine and can bind to the epinephrine receptor.
B) that stimulates cAMP production in liver cells.
C) to stimulate G protein activity in liver cells.
D) that increases phosphodiesterase activity.
E) that does any of the above.